Patents by Inventor Augustinus Petrus Henricus SCHEEFHALS

Augustinus Petrus Henricus SCHEEFHALS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ALPHA-SYNUCLEIN BINDING ANTIBODIES, OR ANTIGEN BINDING PORTIONS THEREOF
    Publication number: 20230151089
    Abstract: The present invention relates to an isolated antibody, or antigen-binding portion thereof, with a higher binding affinity to alpha-synuclein oligomers compared to alpha-synuclein fibrils and/or alpha-synuclein monomers. The invention further describes in vitro and/or ex vivo methods using the isolated antibody, or antigen-binding portion thereof, to detect alpha-synuclein oligomers. The invention further provides a treatment-option for synucleinopathies, or provide a method to diagnose synucleinopathies.
    Type: Application
    Filed: April 12, 2021
    Publication date: May 18, 2023
    Inventors: Augustinus Petrus Henricus SCHEEFHALS, Wilbrandt Jannes Wichert TEPPER, Erik STOOPS
  • Amyloid beta oligomer specific binding molecule
    Patent number: 11104725
    Abstract: This disclosure relates to an amyloid beta peptide (A?)-oligomer-specific antigen binding molecule and the use thereof as a diagnostic agent or as a therapeutic agent for the treatment or prevention of Alzheimer's Disease, Down's syndrome, mild cognitive impairment, cerebral amyloid angiopathy, vascular dementia, multi-infarct dementia, Parkinson's disease, Dementia with Lewy Bodies, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, or Gaucher's disease.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: August 31, 2021
    Assignee: DegenRx B.V.
    Inventors: Samantha Kathleen Cobb, Michael Foley, Augustinus Petrus Henricus Scheefhals, Armand Wilbrandt Jannes Wichert Tepper
  • NOVEL AMYLOID BETA OLIGOMER SPECIFIC BINDING MOLECULE
    Publication number: 20190292247
    Abstract: This disclosure relates to an amyloid beta peptide (A?)-oligomer-specific antigen binding molecule and the use thereof as a diagnostic agent or as a therapeutic agent for the treatment or prevention of Alzheimer's Disease, Down's syndrome, mild cognitive impairment, cerebral amyloid angiopathy, vascular dementia, multi-infarct dementia, Parkinson's disease, Dementia with Lewy Bodies, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, or Gaucher's disease.
    Type: Application
    Filed: November 7, 2017
    Publication date: September 26, 2019
    Inventors: Samantha Kathleen COBB, Michael FOLEY, Augustinus Petrus Henricus SCHEEFHALS, Armand Wilbrandt Jannes Wichert TEPPER